Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases inhibition of mTORC1 and promotes tumor growth.

Padi SKR, Singh N, Bearss JJ, Olive V, Song JH, Cardó-Vila M, Kraft AS, Okumura K.

Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20505-20510. doi: 10.1073/pnas.1904774116. Epub 2019 Sep 23.

PMID:
31548394
2.

Small-Molecule-Targeting Hairpin Loop of hTERT Promoter G-Quadruplex Induces Cancer Cell Death.

Song JH, Kang HJ, Luevano LA, Gokhale V, Wu K, Pandey R, Sherry Chow HH, Hurley LH, Kraft AS.

Cell Chem Biol. 2019 Aug 15;26(8):1110-1121.e4. doi: 10.1016/j.chembiol.2019.04.009. Epub 2019 May 30.

PMID:
31155510
3.

Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.

Chatterjee S, Chakraborty P, Daenthanasanmak A, Iamsawat S, Andrejeva G, Luevano LA, Wolf M, Baliga U, Krieg C, Beeson CC, Mehrotra M, Hill EG, Rathmell JC, Yu XZ, Kraft AS, Mehrotra S.

Clin Cancer Res. 2019 Feb 1;25(3):1036-1049. doi: 10.1158/1078-0432.CCR-18-0706. Epub 2018 Oct 16.

PMID:
30327305
4.

Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase.

Song JH, Singh N, Luevano LA, Padi SKR, Okumura K, Olive V, Black SM, Warfel NA, Goodrich DW, Kraft AS.

Mol Cancer Ther. 2018 Dec;17(12):2710-2721. doi: 10.1158/1535-7163.MCT-18-0374. Epub 2018 Sep 6.

PMID:
30190422
5.

PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity.

Daenthanasanmak A, Wu Y, Iamsawat S, Nguyen HD, Bastian D, Zhang M, Sofi MH, Chatterjee S, Hill EG, Mehrotra S, Kraft AS, Yu XZ.

J Clin Invest. 2018 Jul 2;128(7):2787-2801. doi: 10.1172/JCI95407. Epub 2018 May 21.

6.

Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents.

Casillas AL, Toth RK, Sainz AG, Singh N, Desai AA, Kraft AS, Warfel NA.

Clin Cancer Res. 2018 Jan 1;24(1):169-180. doi: 10.1158/1078-0432.CCR-17-1318. Epub 2017 Oct 30.

7.

Angiosarcoma treated successfully with anti-PD-1 therapy - a case report.

Sindhu S, Gimber LH, Cranmer L, McBride A, Kraft AS.

J Immunother Cancer. 2017 Jul 18;5(1):58. doi: 10.1186/s40425-017-0263-0.

8.

Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.

Padi SKR, Luevano LA, An N, Pandey R, Singh N, Song JH, Aster JC, Yu XZ, Mehrotra S, Kraft AS.

Oncotarget. 2017 May 2;8(18):30199-30216. doi: 10.18632/oncotarget.16320.

9.

PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.

Warfel NA, Sainz AG, Song JH, Kraft AS.

Mol Cancer Ther. 2016 Jul;15(7):1637-47. doi: 10.1158/1535-7163.MCT-15-1018. Epub 2016 May 16.

10.

Insulin receptor substrate 1 is a substrate of the Pim protein kinases.

Song JH, Padi SK, Luevano LA, Minden MD, DeAngelo DJ, Hardiman G, Ball LE, Warfel NA, Kraft AS.

Oncotarget. 2016 Apr 12;7(15):20152-65. doi: 10.18632/oncotarget.7918.

11.

Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors.

An N, Xiong Y, LaRue AC, Kraft AS, Cen B.

Cancer Res. 2015 Dec 15;75(24):5318-28. doi: 10.1158/0008-5472.CAN-15-0544.

12.

PIM kinase (and Akt) biology and signaling in tumors.

Warfel NA, Kraft AS.

Pharmacol Ther. 2015 Jul;151:41-9. doi: 10.1016/j.pharmthera.2015.03.001. Epub 2015 Mar 5. Review.

13.

Regulation of prostate stromal fibroblasts by the PIM1 protein kinase.

Zemskova MY, Song JH, Cen B, Cerda-Infante J, Montecinos VP, Kraft AS.

Cell Signal. 2015 Jan;27(1):135-46. doi: 10.1016/j.cellsig.2014.10.010. Epub 2014 Oct 28.

14.

Deletion of Pim kinases elevates the cellular levels of reactive oxygen species and sensitizes to K-Ras-induced cell killing.

Song JH, An N, Chatterjee S, Kistner-Griffin E, Mahajan S, Mehrotra S, Kraft AS.

Oncogene. 2015 Jul;34(28):3728-36. doi: 10.1038/onc.2014.306. Epub 2014 Sep 22.

15.

The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets.

Saurabh K, Scherzer MT, Shah PP, Mims AS, Lockwood WW, Kraft AS, Beverly LJ.

Oncotarget. 2014 Sep 30;5(18):8503-14.

16.

Reducing CD73 expression by IL1β-Programmed Th17 cells improves immunotherapeutic control of tumors.

Chatterjee S, Thyagarajan K, Kesarwani P, Song JH, Soloshchenko M, Fu J, Bailey SR, Vasu C, Kraft AS, Paulos CM, Yu XZ, Mehrotra S.

Cancer Res. 2014 Nov 1;74(21):6048-59. doi: 10.1158/0008-5472.CAN-14-1450. Epub 2014 Sep 9.

17.

Metabolic dysfunction consistent with premature aging results from deletion of Pim kinases.

Din S, Konstandin MH, Johnson B, Emathinger J, Völkers M, Toko H, Collins B, Ormachea L, Samse K, Kubli DA, De La Torre A, Kraft AS, Gustafsson AB, Kelly DP, Sussman MA.

Circ Res. 2014 Jul 18;115(3):376-87. doi: 10.1161/CIRCRESAHA.115.304441. Epub 2014 Jun 10.

18.

The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling.

Cen B, Xiong Y, Song JH, Mahajan S, DuPont R, McEachern K, DeAngelo DJ, Cortes JE, Minden MD, Ebens A, Mims A, LaRue AC, Kraft AS.

Mol Cell Biol. 2014 Jul;34(13):2517-32. doi: 10.1128/MCB.00147-14. Epub 2014 Apr 28.

19.

The 2014 Surgeon General's report: "The health consequences of smoking--50 years of progress": a paradigm shift in cancer care.

Warren GW, Alberg AJ, Kraft AS, Cummings KM.

Cancer. 2014 Jul 1;120(13):1914-6. doi: 10.1002/cncr.28695. Epub 2014 Mar 28. No abstract available.

20.

Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma.

Marshall DT, Ramey S, Golshayan AR, Keane TE, Kraft AS, Chaudhary U.

Clin Genitourin Cancer. 2014 Apr;12(2):80-6. doi: 10.1016/j.clgc.2013.11.019. Epub 2013 Nov 13.

PMID:
24378335
21.

Targeted glycoprotein enrichment and identification in stromal cell secretomes using azido sugar metabolic labeling.

Roper SM, Zemskova M, Neely BA, Martin A, Gao P, Jones EE, Kraft AS, Drake RR.

Proteomics Clin Appl. 2013 Jun;7(5-6):367-71. doi: 10.1002/prca.201300006.

22.

A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.

Twardowski PW, Beumer JH, Chen CS, Kraft AS, Chatta GS, Mitsuhashi M, Ye W, Christner SM, Lilly MB.

Anticancer Drugs. 2013 Aug;24(7):743-53. doi: 10.1097/CAD.0b013e328361feb0.

23.

Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1.

Cen B, Mahajan S, Wang W, Kraft AS.

Cancer Res. 2013 Jun 1;73(11):3402-11. doi: 10.1158/0008-5472.CAN-12-4619. Epub 2013 Apr 12.

24.

Pim1 serine/threonine kinase regulates the number and functions of murine hematopoietic stem cells.

An N, Lin YW, Mahajan S, Kellner JN, Wang Y, Li Z, Kraft AS, Kang Y.

Stem Cells. 2013 Jun;31(6):1202-12. doi: 10.1002/stem.1369.

25.

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.

Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG.

Lancet Oncol. 2013 Apr;14(4):371-82. doi: 10.1016/S1470-2045(13)70049-4. Epub 2013 Mar 8.

26.

Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice.

An N, Kraft AS, Kang Y.

J Hematol Oncol. 2013 Jan 29;6:12. doi: 10.1186/1756-8722-6-12.

27.

Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer.

Cai H, Memarzadeh S, Stoyanova T, Beharry Z, Kraft AS, Witte ON.

Cancer Res. 2012 Sep 15;72(18):4672-81. Epub 2012 Jul 17.

28.

Multiple phosphorylation sites are important for RUNX1 activity in early hematopoiesis and T-cell differentiation.

Yoshimi M, Goyama S, Kawazu M, Nakagawa M, Ichikawa M, Imai Y, Kumano K, Asai T, Mulloy JC, Kraft AS, Takahashi T, Shirafuji N, Kurokawa M.

Eur J Immunol. 2012 Apr;42(4):1044-50. doi: 10.1002/eji.201040746.

29.

Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737.

Song JH, Kraft AS.

Cancer Res. 2012 Jan 1;72(1):294-303. doi: 10.1158/0008-5472.CAN-11-3240. Epub 2011 Nov 11.

30.

Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade.

Kraft AS, Garrett-Mayer E, Wahlquist AE, Golshayan A, Chen CS, Butler W, Bearden J, Lilly M.

Cancer Biol Ther. 2011 Jul 15;12(2):119-24. Epub 2011 Jul 15.

PMID:
21532336
31.

The Pim protein kinases regulate energy metabolism and cell growth.

Beharry Z, Mahajan S, Zemskova M, Lin YW, Tholanikunnel BG, Xia Z, Smith CD, Kraft AS.

Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):528-33. doi: 10.1073/pnas.1013214108. Epub 2010 Dec 27.

32.

The BH3 mimetic ABT-737 induces cancer cell senescence.

Song JH, Kandasamy K, Zemskova M, Lin YW, Kraft AS.

Cancer Res. 2011 Jan 15;71(2):506-15. doi: 10.1158/0008-5472.CAN-10-1977. Epub 2010 Nov 16.

33.

Regulation of Skp2 levels by the Pim-1 protein kinase.

Cen B, Mahajan S, Zemskova M, Beharry Z, Lin YW, Cramer SD, Lilly MB, Kraft AS.

J Biol Chem. 2010 Sep 17;285(38):29128-37. doi: 10.1074/jbc.M110.137240. Epub 2010 Jul 27.

34.

p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase.

Zemskova M, Lilly MB, Lin YW, Song JH, Kraft AS.

Mol Cancer Res. 2010 Aug;8(8):1126-41. doi: 10.1158/1541-7786.MCR-10-0174. Epub 2010 Jul 20.

35.

A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.

Lin YW, Beharry ZM, Hill EG, Song JH, Wang W, Xia Z, Zhang Z, Aplan PD, Aster JC, Smith CD, Kraft AS.

Blood. 2010 Jan 28;115(4):824-33. doi: 10.1182/blood-2009-07-233445. Epub 2009 Nov 23.

36.

Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells.

Beharry Z, Zemskova M, Mahajan S, Zhang F, Ma J, Xia Z, Lilly M, Smith CD, Kraft AS.

Mol Cancer Ther. 2009 Jun;8(6):1473-83. doi: 10.1158/1535-7163.MCT-08-1037. Epub 2009 Jun 9.

37.

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, Elias AD, Brockstein B, Blachère NE, Edgar MA, Schwartz LH, Qin LX, Antonescu CR, Schwartz GK.

J Clin Oncol. 2009 Jul 1;27(19):3133-40. doi: 10.1200/JCO.2008.20.4495. Epub 2009 May 18.

38.

PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells.

Zhang F, Beharry ZM, Harris TE, Lilly MB, Smith CD, Mahajan S, Kraft AS.

Cancer Biol Ther. 2009 May;8(9):846-53. Epub 2009 May 18.

PMID:
19276681
39.

Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.

Xia Z, Knaak C, Ma J, Beharry ZM, McInnes C, Wang W, Kraft AS, Smith CD.

J Med Chem. 2009 Jan 8;52(1):74-86. doi: 10.1021/jm800937p.

40.

ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis.

Song JH, Kandasamy K, Kraft AS.

J Biol Chem. 2008 Sep 5;283(36):25003-13. doi: 10.1074/jbc.M802511200. Epub 2008 Jul 3.

41.

Hypoxia-inducible factor-2alpha regulates the expression of TRAIL receptor DR5 in renal cancer cells.

Mahajan S, Dammai V, Hsu T, Kraft AS.

Carcinogenesis. 2008 Sep;29(9):1734-41. doi: 10.1093/carcin/bgn132. Epub 2008 Jun 9.

42.

Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue Sarcomas.

von Mehren M, Balcerzak SP, Kraft AS, Edmonson JH, Okuno SH, Davey M, McLaughlin S, Beard MT, Rogatko A.

Sarcoma. 2004;8(4):107-11. doi: 10.1080/13577140400009163.

43.

Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region.

Kandasamy K, Kraft AS.

Mol Cancer Ther. 2008 May;7(5):1091-100. doi: 10.1158/1535-7163.MCT-07-2368.

44.

Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer.

Beldner MA, Sherman CA, Green MR, Garrett-Mayer E, Chaudhary U, Meyer ML, Kraft AS, Montero AJ.

BMC Cancer. 2007 Dec 20;7:231.

45.

Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy.

Xiong X, Sui M, Fan W, Kraft AS.

Cancer Biol Ther. 2007 Jul;6(7):1067-73.

PMID:
17568189
46.

Negative regulation of Pim-1 protein kinase levels by the B56beta subunit of PP2A.

Ma J, Arnold HK, Lilly MB, Sears RC, Kraft AS.

Oncogene. 2007 Aug 2;26(35):5145-53. Epub 2007 Feb 12.

PMID:
17297438
47.

Regulation of RUNX1/AML1 during the G2/M transition.

Wang S, Zhang Y, Soosairajah J, Kraft AS.

Leuk Res. 2007 Jun;31(6):839-51. Epub 2006 Oct 4.

PMID:
17023045
48.

AML1/RUNX1 phosphorylation by cyclin-dependent kinases regulates the degradation of AML1/RUNX1 by the anaphase-promoting complex.

Biggs JR, Peterson LF, Zhang Y, Kraft AS, Zhang DE.

Mol Cell Biol. 2006 Oct;26(20):7420-9. Epub 2006 Aug 5.

49.

Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis.

Sui M, Xiong X, Kraft AS, Fan W.

Cancer Biol Ther. 2006 Aug;5(8):1015-21. Epub 2006 Aug 18.

PMID:
16855376
50.

Pim family kinases enhance tumor growth of prostate cancer cells.

Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS.

Mol Cancer Res. 2005 Aug;3(8):443-51.

Supplemental Content

Loading ...
Support Center